SNC PHARMACIE FLAHAUT ET ARCHAMBAULT : revenue, balance sheet and financial ratios

SNC PHARMACIE FLAHAUT ET ARCHAMBAULT is a French company founded 32 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in MENNECY (91540), this company of category PME shows in 2022 a revenue of 5.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SNC PHARMACIE FLAHAUT ET ARCHAMBAULT (SIREN 392361002)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017
Revenue N/C N/C N/C 5 306 186 € 4 714 642 € 4 731 746 € 4 565 014 € N/C 4 014 651 €
Net income 65 537 € 35 042 € 209 687 € 310 303 € 83 496 € 54 910 € 91 224 € 65 145 € 64 221 €
EBITDA N/C N/C N/C 459 571 € 141 810 € 130 144 € 149 536 € N/C 77 212 €
Net margin N/C N/C N/C 5.8% 1.8% 1.2% 2.0% N/C 1.6%

Revenue and income statement

In 2025, SNC PHARMACIE FLAHAUT ET ARCHAMBAULT generates positive net income of 66 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 64 k€ -> 66 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

65 537 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 887%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 6%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

886.599%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

6.35%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

17.0%

Solvency indicators evolution
SNC PHARMACIE FLAHAUT ET ARCHAMBAULT

Sector positioning

Debt ratio
886.6 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Watch +12 pts over 3 years

In 2025, the debt ratio of SNC PHARMACIE FLAHAUT ET ... (886.60) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
6.35% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Watch

In 2025, the financial autonomy of SNC PHARMACIE FLAHAUT ET ... (6.3%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 101.50. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

101.495

Liquidity indicators evolution
SNC PHARMACIE FLAHAUT ET ARCHAMBAULT

Sector positioning

Liquidity ratio
101.5 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch

In 2025, the liquidity ratio of SNC PHARMACIE FLAHAUT ET ... (101.50) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SNC PHARMACIE FLAHAUT ET ARCHAMBAULT

Positioning of SNC PHARMACIE FLAHAUT ET ARCHAMBAULT in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of SNC PHARMACIE FLAHAUT ET ARCHAMBAULT is estimated at 1 041 063 € (range 706 470€ - 1 633 571€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
706k€ 1041k€ 1633k€
1 041 063 € Range: 706 470€ - 1 633 571€
NAF 5 année 2025

Valuation method used

Net Income Multiple
65 537 € × 15.9x = 1 041 063 €
Range: 706 470€ - 1 633 571€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SNC PHARMACIE FLAHAUT ET ARCHAMBAULT with other companies in the same sector:

Frequently asked questions about SNC PHARMACIE FLAHAUT ET ARCHAMBAULT

What is the revenue of SNC PHARMACIE FLAHAUT ET ARCHAMBAULT ?

The revenue of SNC PHARMACIE FLAHAUT ET ARCHAMBAULT in 2022 is 5.3 M€.

Is SNC PHARMACIE FLAHAUT ET ARCHAMBAULT profitable?

Yes, SNC PHARMACIE FLAHAUT ET ARCHAMBAULT generated a net profit of 66 k€ in 2025.

Where is the headquarters of SNC PHARMACIE FLAHAUT ET ARCHAMBAULT ?

The headquarters of SNC PHARMACIE FLAHAUT ET ARCHAMBAULT is located in MENNECY (91540), in the department Essonne.

Where to find the tax return of SNC PHARMACIE FLAHAUT ET ARCHAMBAULT ?

The tax return of SNC PHARMACIE FLAHAUT ET ARCHAMBAULT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SNC PHARMACIE FLAHAUT ET ARCHAMBAULT operate?

SNC PHARMACIE FLAHAUT ET ARCHAMBAULT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.